Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

917 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-grade albuminuria and cardiovascular risk : what is the evidence?
Schmieder RE, Schrader J, Zidek W, Tebbe U, Paar WD, Bramlage P, Pittrow D, Böhm M. Schmieder RE, et al. Among authors: schrader j. Clin Res Cardiol. 2007 May;96(5):247-57. doi: 10.1007/s00392-007-0510-3. Epub 2007 Apr 26. Clin Res Cardiol. 2007. PMID: 17453140 Review.
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO Study Group. Lüders S, et al. Among authors: schrader j. J Hypertens. 2008 Jul;26(7):1487-96. doi: 10.1097/HJH.0b013e3282ff8864. J Hypertens. 2008. PMID: 18551027 Clinical Trial.
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.
Schrader J, Lüders S, Kulschewski A, Hammersen F, Züchner C, Venneklaas U, Schrandt G, Schnieders M, Rangoonwala B, Berger J, Dominiak P, Zidek W; MARPLE Study Group. Schrader J, et al. J Hypertens. 2006 Mar;24(3):541-8. doi: 10.1097/01.hjh.0000209991.48928.c4. J Hypertens. 2006. PMID: 16467658 Clinical Trial.
Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Zemmrich C, Lüders S, Gansz A, Sturm CD, Fimmers R, Nadal J, Schmieder RE, Schrader J, Bramlage P. Zemmrich C, et al. Among authors: schrader j. J Clin Hypertens (Greenwich). 2013 Nov;15(11):815-9. doi: 10.1111/jch.12202. Epub 2013 Sep 16. J Clin Hypertens (Greenwich). 2013. PMID: 24102831 Free PMC article. Clinical Trial.
Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2).
Bramlage P, Zemmrich C, Gansz A, Sturm CD, Fimmers R, Nadal J, Schmieder RE, Schrader J, Lüders S. Bramlage P, et al. Among authors: schrader j. J Clin Hypertens (Greenwich). 2014 Jan;16(1):41-6. doi: 10.1111/jch.12227. Epub 2013 Nov 8. J Clin Hypertens (Greenwich). 2014. PMID: 24410942 Free PMC article. Clinical Trial.
917 results